Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alison Oliveto

Concepts (180)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Opioid-Related Disorders
23
2025
426
5.080
Why?
Cocaine-Related Disorders
21
2025
206
3.930
Why?
Methadone
16
2025
187
2.900
Why?
Narcotic Antagonists
11
2025
150
2.760
Why?
Buprenorphine
12
2025
162
2.590
Why?
Opiate Substitution Treatment
7
2025
114
2.010
Why?
Naltrexone
3
2025
70
1.940
Why?
Substance Withdrawal Syndrome
7
2025
168
1.850
Why?
Disulfiram
3
2025
13
1.600
Why?
Double-Blind Method
23
2025
729
1.370
Why?
Alcohol Deterrents
2
2025
10
1.270
Why?
Sertraline
3
2017
48
1.260
Why?
Naloxone
5
2013
85
1.180
Why?
Narcotics
11
2025
108
0.990
Why?
Heart Rate
3
2025
313
0.920
Why?
Analgesics, Opioid
7
2023
622
0.890
Why?
Adult
39
2026
14541
0.890
Why?
Cyclohexanecarboxylic Acids
3
2014
18
0.860
Why?
Amines
3
2014
38
0.860
Why?
gamma-Aminobutyric Acid
3
2014
61
0.840
Why?
Methadyl Acetate
3
2010
11
0.820
Why?
Amphetamine-Related Disorders
3
2021
93
0.750
Why?
Dose-Response Relationship, Drug
11
2025
1367
0.730
Why?
Middle Aged
25
2026
13422
0.710
Why?
Video Games
1
2022
14
0.710
Why?
Methamphetamine
3
2021
190
0.700
Why?
Cocaine
7
2025
168
0.670
Why?
Male
37
2026
27444
0.650
Why?
Female
36
2026
28792
0.620
Why?
Prescription Drug Misuse
1
2019
37
0.570
Why?
Drug Monitoring
1
2019
81
0.570
Why?
Humans
49
2026
53246
0.550
Why?
Depression
2
2014
621
0.520
Why?
Dopamine Uptake Inhibitors
3
2007
54
0.520
Why?
Outpatients
3
2025
131
0.470
Why?
Databases, Factual
1
2019
742
0.460
Why?
Remote Consultation
1
2015
30
0.460
Why?
Neurology
1
2015
33
0.450
Why?
Desipramine
6
2005
26
0.430
Why?
Isradipine
2
2004
4
0.410
Why?
Rural Health Services
1
2015
179
0.390
Why?
Treatment Outcome
11
2025
5597
0.390
Why?
Diltiazem
1
2013
10
0.390
Why?
Verapamil
1
2013
19
0.390
Why?
Excitatory Amino Acid Antagonists
1
2013
46
0.390
Why?
Emergency Service, Hospital
4
2021
530
0.380
Why?
Calcium Channel Blockers
1
2013
57
0.370
Why?
Electrocardiography
1
2013
272
0.340
Why?
Behavior Therapy
2
2010
185
0.320
Why?
Sodium Oxybate
1
2010
11
0.320
Why?
Pilot Projects
8
2021
727
0.320
Why?
Behavior
1
2010
46
0.320
Why?
Bupropion
2
2007
34
0.310
Why?
Hypnotics and Sedatives
1
2010
74
0.310
Why?
Combined Modality Therapy
5
2017
640
0.300
Why?
Benzhydryl Compounds
1
2009
70
0.290
Why?
Citalopram
1
2007
17
0.260
Why?
Drug Therapy, Combination
5
2014
405
0.250
Why?
Feedback
2
2023
53
0.220
Why?
Adrenergic Uptake Inhibitors
1
2005
14
0.220
Why?
Stress Disorders, Post-Traumatic
1
2010
411
0.210
Why?
Dextromethorphan
1
2004
16
0.210
Why?
Young Adult
6
2026
4514
0.210
Why?
Antidepressive Agents, Tricyclic
5
2004
28
0.210
Why?
Discrimination Learning
1
2004
58
0.200
Why?
Stress, Psychological
1
2026
283
0.200
Why?
Cycloserine
1
2003
3
0.200
Why?
Antimetabolites
1
2003
12
0.200
Why?
Behavior Control
1
2003
3
0.200
Why?
Diagnosis, Dual (Psychiatry)
3
2014
42
0.190
Why?
Tai Ji
1
2023
22
0.190
Why?
Behavior, Addictive
1
2003
62
0.190
Why?
Smoking Cessation
1
2026
325
0.190
Why?
Smoking
1
2026
526
0.180
Why?
Secondary Prevention
2
2013
85
0.180
Why?
Nalbuphine
1
2002
2
0.180
Why?
Butorphanol
1
2002
6
0.180
Why?
Prospective Studies
3
2019
2412
0.170
Why?
Dextroamphetamine
1
2021
36
0.170
Why?
Emotions
1
2023
177
0.170
Why?
Placebos
4
2011
80
0.170
Why?
Heroin Dependence
4
2006
46
0.170
Why?
GABA Agonists
2
2014
13
0.170
Why?
Predictive Value of Tests
2
2019
933
0.170
Why?
Patient Compliance
2
2014
232
0.160
Why?
Self Report
2
2013
225
0.160
Why?
Chromatography, High Pressure Liquid
1
2021
333
0.160
Why?
Guideline Adherence
1
2021
143
0.160
Why?
Psychomotor Agitation
1
2020
51
0.150
Why?
Blood Pressure
3
2011
518
0.150
Why?
Tandem Mass Spectrometry
1
2021
255
0.150
Why?
Adolescent
3
2022
6912
0.150
Why?
Central Nervous System Stimulants
1
2021
201
0.150
Why?
Severity of Illness Index
2
2013
1049
0.140
Why?
Antipsychotic Agents
1
2020
233
0.140
Why?
Retrospective Studies
4
2022
6821
0.140
Why?
Ambulatory Care
3
2011
239
0.140
Why?
Risk Assessment
2
2020
1368
0.130
Why?
Effect Modifier, Epidemiologic
1
2017
7
0.130
Why?
Pain Management
1
2019
185
0.130
Why?
Area Under Curve
2
2010
185
0.120
Why?
Chronic Pain
1
2019
183
0.120
Why?
Analysis of Variance
5
2004
547
0.120
Why?
Mass Screening
1
2019
362
0.120
Why?
Psychiatric Status Rating Scales
4
2011
325
0.120
Why?
Transportation
1
2015
30
0.120
Why?
Time Factors
3
2011
2992
0.120
Why?
Travel
1
2015
37
0.110
Why?
Nipecotic Acids
2
2006
2
0.110
Why?
Diagnostic and Statistical Manual of Mental Disorders
2
2013
77
0.110
Why?
Tissue Plasminogen Activator
1
2015
108
0.110
Why?
Cognition
2
2023
346
0.110
Why?
Anxiety
2
2022
321
0.100
Why?
Recurrence
2
2014
694
0.100
Why?
Directly Observed Therapy
1
2013
5
0.100
Why?
Socioeconomic Factors
1
2015
623
0.100
Why?
Maintenance Chemotherapy
1
2013
52
0.100
Why?
Patient Dropouts
1
2013
52
0.100
Why?
Induction Chemotherapy
1
2013
65
0.100
Why?
Calcium Channels, L-Type
1
2013
68
0.090
Why?
Medication Adherence
1
2014
136
0.090
Why?
Drug Interactions
1
2013
196
0.090
Why?
Depressive Disorder, Major
2
2004
149
0.090
Why?
Injections, Intramuscular
2
2020
55
0.090
Why?
Confusion
1
2010
19
0.080
Why?
Substance Abuse Treatment Centers
1
2011
83
0.080
Why?
Affect
1
2011
107
0.080
Why?
Kaplan-Meier Estimate
1
2011
487
0.080
Why?
Respiration
1
2010
94
0.080
Why?
Arkansas
1
2015
2068
0.080
Why?
Psychomotor Performance
1
2010
126
0.080
Why?
Magnetic Resonance Imaging
3
2026
1587
0.070
Why?
Sleep
1
2011
196
0.070
Why?
Hemodynamics
1
2010
236
0.070
Why?
Alcohol Drinking
1
2010
241
0.070
Why?
Connecticut
2
2005
17
0.070
Why?
Progestins
1
2007
10
0.070
Why?
Progesterone
1
2007
57
0.070
Why?
Sex Characteristics
1
2008
204
0.060
Why?
Substance Abuse Detection
2
2006
93
0.060
Why?
Anti-Anxiety Agents
1
2006
34
0.060
Why?
Anxiety Disorders
1
2007
133
0.060
Why?
Cues
1
2006
56
0.060
Why?
Urinalysis
1
2005
33
0.050
Why?
Depressive Disorder
1
2007
336
0.050
Why?
Linear Models
2
2021
287
0.050
Why?
GABA Agents
1
2003
3
0.050
Why?
Token Economy
1
2003
33
0.050
Why?
Prefrontal Cortex
1
2023
85
0.050
Why?
Tobacco Use Disorder
1
2004
174
0.050
Why?
Prognosis
2
2005
2118
0.050
Why?
Pain Measurement
1
2003
259
0.050
Why?
Ketoconazole
1
2002
10
0.050
Why?
Reproducibility of Results
2
2021
1221
0.040
Why?
Limit of Detection
1
2021
21
0.040
Why?
Pain
1
2023
353
0.040
Why?
Controlled Clinical Trials as Topic
1
2020
21
0.040
Why?
Clinical Trials as Topic
1
2002
466
0.040
Why?
California
1
2019
93
0.040
Why?
Ambulatory Care Facilities
1
2019
121
0.030
Why?
Practice Guidelines as Topic
1
2021
502
0.030
Why?
Brain
1
2006
1353
0.030
Why?
Randomized Controlled Trials as Topic
1
2020
630
0.030
Why?
Drug Administration Schedule
2
2006
370
0.030
Why?
Adrenergic alpha-2 Receptor Agonists
2
2004
9
0.020
Why?
Comorbidity
2
2006
638
0.020
Why?
Aged
3
2019
10430
0.020
Why?
Echo-Planar Imaging
1
2006
11
0.010
Why?
Photic Stimulation
1
2006
56
0.010
Why?
Reward
1
2006
119
0.010
Why?
Interview, Psychological
1
2004
24
0.010
Why?
Cerebral Cortex
1
2006
194
0.010
Why?
Receptors, Opioid, mu
1
2004
53
0.010
Why?
Oxygen
1
2006
338
0.010
Why?
Psychometrics
1
2004
244
0.010
Why?
Receptors, Opioid
1
2002
16
0.010
Why?
Chi-Square Distribution
1
2002
291
0.010
Why?
Cross-Over Studies
1
2002
241
0.010
Why?
Proportional Hazards Models
1
2002
445
0.010
Why?
Antifungal Agents
1
2002
350
0.010
Why?
Oliveto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description